Elucidating the molecular etiology of schizophrenia and genetic determinants of efficacy after treatment with an antipsychotic has been a desirable but challenging goal [1] . Studies have evaluated the impact of specific dopamine (D) and serotonin (5-HT) receptor mutations on patient response to clozapine, an agent generally reserved for use in severely ill patients who have failed treatment with other antipsychotics [2] [3] [4] . Information is limited regarding the association between D 3 and 5-HT 6 receptor polymorphisms and responses to risperidone, a more commonly prescribed agent [5, 6] . Despite studies such as those conducted by Arranz et al., Hwang et al. and Lane et al. [2] [3] [4] [5] [6] , we still know little regarding genetic influences on responses to antipsychotic therapy. Expanding our knowledge in this area may allow for individualized therapy and improved patient outcomes. Dysfunction in neurotrophic factors, which play an important role in neural development and differentiation, may contribute to susceptibility to schizophrenia and related disorders. Ciliary neurotrophic factor (CNTF) is a multifunctional cytokine in the interleukin 6 family that supports the survival and/or differentiation of a variety of neuronal and other cell types [7, 8] . In cultured neural cells, CNTF has been shown to regulate neurotransmitter formation and phenotype, in particular the decrease of dopamine β-hydroxylase activity and serotonin synthesis and the increase in choline acetyltransferase activity [9] [10] [11] . Several lines of evidence underscore the neurotrophic and neuroprotective effects of CNTF in vivo [7, [12] [13] [14] . CNTF has been shown to be a survivalpromoting factor for parasympathetic ciliary ganglion and sensory, motor, retinal and cortical neurons [15] . CNTF also has been shown to be required for motor neuron axonal sprouting in adult mice [16] , and in promoting neuronal survival after brain damage in experimental animals [17] . Moreover, the CNTF protein is a potent survival factor for oligodendrocytes, and recent studies of post-mortem brains have revealed the existence of a deficit of perineuronal and pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia [18, 19] . Necrosis and apoptosis of oligodendrocytes have been demonstrated in schizophrenia by electron microscopy, which suggests a key role of damage and loss of oligodendrocytes in altered neuronal connectivity and in atrophy of neurons in schizophrenia [20] . Evidence also shows that CNTF may modulate monoaminergic neurotransmitter phenotype [9, 13, 21] , primarily in the prenatal period [10] . The role of CNTF as a neuroprotectant indicates that disruption of CNTF expression during neural development may result in altered CNS function. The most extensively studied CNTF gene polymorphism is rs1800169 [101] , a G to A transition close to the boundary between the first intron and second exon. As a result of this transition, four ribonucleotides are inserted into the CNTF mRNA, producing a frameshift and a premature stop codon. Functional protein can not be made from the null allele (A), also referred to as FS63TER [22] . Approximately 24% of white populations, 10% of black populations and 28% of Japanese populations have a non-G/G genotype, with only 3.0% or less who are A/A homozygotes in these populations [23, 24] . The CNTF FS63TER allele has been associated with an increased risk for schizophrenia or schizoaffective disorder in some studies [25] [26] [27] , although this finding is inconsistent [24, 28, 29] . Investigators have suggested that the positive relationship between the CNTF null allele and the occurrence of schizophrenia may result from decreased trophic support for vulnerable neurons, leading to a developmental disorder that increases the risk for schizophrenia [25] . While a role of FS63TER in the etiology of schizophrenia has been postulated and studied by many groups, its influence on antipsychotic treatment response has not been reported.
Iloperidone is a mixed D 2 /5-HT 2 antagonist antipsychotic in development for the treatment of schizophrenia. In controlled clinical trials, iloperidone has demonstrated safety and efficacy in the treatment of schizophrenia [30] . In the course of the Phase III clinical development, a pharmacogenetic investigation was previously conducted in a randomized clinical trial to identify markers of iloperidone response. Polymorphisms in a few selected genes believed to be involved in the etiology of schizophrenia and/or the efficacy response to antipsychotics were investigated, including the genes encoding the dopamine receptors D2 and D3 (DRD2 and DRD3), dopamine β-hydroxylase (DBH), 5-HT receptor 1B (HTR1B) and the CNTF. A SNP, rs1800169 located in the CNTF gene, correlated significantly with symptom improvement after iloperidone treatment. Significantly greater improvement in the Positive and Negative Syndrome Scale total (PANSS-T) score for patients with the G/G genotype versus those with the non-G/G genotype was seen with iloperidone treatment (p = 0.0017). When the iloperidone and placebo responses were compared, the improvement in PANSS-T was significant for patients with the G/G genotype (p = 0.050), but not for those with the non-G/G genotype (p = 0.69). The potential relationship between CNTF genotype and response to iloperidone identified in this analysis warranted further evaluation. Therefore, efficacy response to iloperidone and placebo in patients with schizophrenia was prospectively assessed based on CNTF genotypes as part of the step-down primary objective in a subsequent Phase III trial.
The current 4-week study used a prospective, randomized, double-blind, placebo-and activecontrolled design. The primary objective was to compare the efficacy of iloperidone 24 mg/day with that of placebo, as measured by the change from baseline to end point in PANSS-T scores. A step-down primary objective was to evaluate the difference in mean PANSS-T change from baseline to day 28 between iloperidone and placebo in patients with the CNTF rs1800169 G/G genotype. An additional analysis evaluated the interaction between patient race and CNTF genotype. The results of this pharmacogenetic study are reported here.
Patients & methods
The study protocol and informed consent forms were approved by institutional review boards or independent ethics committees. Each patient signed an informed consent form before participating. This study was conducted in accordance with the Declaration of Helsinki, the US Code of Federal Regulations governing the protection of human subjects and obligations of clinical investigators, and Good Clinical Practice and ICH guidelines. The design and overall results of this Phase III trial have been reported previously and are briefly summarized here [31] .
Study design
This was a prospective 4-week, randomized, double-blind, placebo-and active-controlled inpatient study. The primary objective was to compare the efficacy of iloperidone 24 mg/day with that of placebo, as measured by the change from baseline to end point in the PANSS-T. The PANSS scale is a 30-item, 7-point rating instrument developed and standardized for typological and dimensional assessment of schizophrenia [32] that evaluates positive, negative and general psychopathological symptoms. If this comparison had achieved significance (p < 0.05) for the primary efficacy variable, an additional comparison of the efficacy of iloperidone versus placebo in patients with the rs1800169 G/G CNTF genotype would be performed.
Eligible patients were aged 18-65 years with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision [33] diagnosis of schizophrenia, Clinical Global Impression of Severity (CGI-S) score of 4 or more, PANSS-T score of at least 70 at screening and at baseline and ratings of at least 4 on two or more PANSS positive subscale (PANSS-P) symptoms at screening and at baseline. Most patients had prior hospitalization for schizophrenia and had been taking psychotropic medication before entering the study. Patients were allowed to take their prior antipsychotic medications up until day -1; no additional washout was required. All patients were in need of psychiatric treatment.
Patients were randomly assigned (2:1:1) to receive iloperidone, placebo or the active comparator, ziprasidone. Titration from days 1 through 7 using a fixed dosing regimen reached the specified target doses, which were then continued through to day 28. The study drug was 
BPRS: Brief Psychiatric Rating Scale; CGI-S: Clinical Global Impression of Severity; PANSS: Positive and Negative syndrome Scale; PANSS-GP: PANSS General Psychopathology subscale; PANSS-N: PANSS Negative subscale; PANSS-P: PANSS Positive subscale; PANSS-T: Positive and Negative Syndrome Scale total.
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future science group future science group administered by the investigative site personnel, and medication compliance was verified by means of buccal examination. All patients underwent psychiatric assessment at screening, at baseline, and on days 7, 10, 14, 21 and 28 after treatment began. The PANSS-T, the PANSS-derived Brief Psychiatric Rating Scale (BPRS), PANSS-P, PANSS negative subscale (PANSS-N), PANSS general psychopathology subscale (PANSS-GP), CGI-S (1 = normal, not at all ill; 7 = among most extremely ill) and the Clinical Global Impression of Change (CGI-C; 4 = no change; <4 = improvement; and > 4 = worsening) were used by qualified personnel trained to assess efficacy. Ratings were only completed by a qualified or trained healthcare professional (MD, DO, PhD, Pharm.D, BA, or BS). Only those raters qualified by the United BioSource Corporation (formerly known as PharmaStar) were allowed to rate in this study. Raters were required to have at least 1 year of experience using these scales or comparable instruments in rating patients with psychiatric disorders. Each site had to have at least two certified raters for the PANSS scale. The study was not initiated at a site without evidence of acceptable inter-rater reliability.
DNA extraction & genotyping
Blood samples were collected at baseline. DNA was extracted and genotyped by Quest Diagnostics Nichols Institute (San Juan Capistrano, CA, USA). DNA extraction was carried out using a Qiagen 9604 BioRobot. A genomic region containing the rs1800169 locus was PCR amplified. The PCR product was treated with calf intestinal phosphatase and exonuclease I to remove unincorporated dNTPs and PCR primers. This was followed by single nucleotide primer extension reaction [34] . This approach was validated by a different genotyping method, where the PCR product generated with primers (5´-ACA CAT TTG TGC ATC TGT AAC CA-3´ and 5´-TGA TAC TAT GAA TTT GGG GAC TTC G -3´) was used in an Invader Assay ® as recommended by the manufacturer (Third Wave Technologies, Madison, WI, USA).
Statistical analysis
The efficacy analysis was based on the modified intent-to-treat (ITT) population [31] , which included all randomly assigned patients who received at least one dose of study medication and had at least one post-baseline efficacy measurement. The primary efficacy end point was the change from baseline to the last scheduled assessment (day 28) in mean PANSS-T, which was analyzed using mixed-effects model repeated measures (MMRM). Analysis of variance was used to test the primary null hypothesis that there was no difference between the iloperidone and placebo groups in PANSS-T change from baseline. Also tested as a stepdown primary objective was the null hypothesis of no difference in mean PANSS-T change from baseline to day 28 between iloperidone and placebo in patients with the CNTF rs1800169 G/G genotype. Since homozygote patients for the A allele were expected to be rare, they were analyzed for all comparisons together with the G/A heterozygotes, as was done in the previous pharmacogenetic study. Therefore, the non-G/G genotype group included patients with one or two null FS63TER alleles. An additional post hoc analysis evaluated the interaction between patient future science group future science group race and CNTF genotype with regard to the step-down end point. Response to iloperidone and to placebo for G/G and non-G/G patients in specific racial groups was compared using the MMRM method.
Results
Patients
A total of 423 patients (283 iloperidone; and 140 placebo) met the criteria for the randomized ITT population in the primary step-down pharmacogenetic analysis. Discontinuation due to adverse events or lack of efficacy was lower in the iloperidone group (12.5%) than in the placebo group (20.1%) [31] . A total of 193 (65.4%) patients in the iloperidone group and 90 (60.4%) in the placebo group completed the 4-week study. There were 417 patients (279 iloperidone; 138 placebo; Table 1 ) with rs1800169 CNTF genotype results available for analysis. Of these patients, 325 (78%) had the G/G genotype and 92 (22%) were non-G/G. The three ethnic/racial groups with the largest number of genotyped patients were blacks (n = 211, 50.6%), whites (n = 143, 34.3%) and Asians (n = 39, 9.4%). Additional ethnic/racial groups that included American Indians, Native Alaskans, Native Hawaiians, Pacific Islanders or others, contained only 24 (5.7%) genotyped patients (Table 1) . No significant differences in efficacy baseline values were observed between the two rs1800169 CNTF genotype classes (G/G and non-G/G) (Table 1) .
Response to iloperidone PANSS Overall, iloperidone was significantly more effective than placebo in improving PANSS-T scores (12.01 vs 7.08 points of improvement, respectively; p = 0.006) (Figure 1 ). Within the iloperidone group, patients showed similar improvement regardless of their rs1800169 CNTF genotype. A significant difference in PANSS-T score improvement was observed between the iloperidone and placebo groups among the G/G patients (12.05 vs 5.68 points respectively; p = 0.002), but not among the non-G/G patients (12.16 vs 12.25 points) (Figure 1) . However, as observed in the previous pharmacogenetic study, CNTF genotypes had a marked effect on response within the placebo group. The rs1800169 G/G genotype was carried by 78.1 and 77.5% of patients in the iloperidone and placebo groups, respectively, similar to what had been observed in the previous study (78.3%). However, substantial genotype frequency differences existed between populations (χ 2 p = 0.008), where the G/G genotype was more common among blacks (84.4%) than among Asians (76.9%) and whites (70.6%; Table 1 ). Despite these differences, the greater efficacy response of the G/G genotype was still observed in both black and white populations (p = 0.02) ( Table 2 ).
PANSS subscales
The same effect of the rs1800169 CNTF genotype was observed in the PANSS subscales. Iloperidone significantly improved PANSS-P (p < 0.001) and PANSS-N (p = 0.027) scores versus placebo in the overall patient population (Figures 2 & 3) . Improvement from baseline in PANSS-GP scores (Figure 4) was also greater in the overall patient population with iloperidone than with placebo, but did not reach statistical significance (p = 0.062). As observed for the PANSS-T scale, the improvement over placebo was significantly greater for patients with the G/G genotype in all three subscales (PANSS-P, p < 0.001; PANSS-N, p = 0.004; PANSS-GP, p = 0.026) than for those with the non-G/G genotype (all p > 0.05). Similar to PANSS-T, the CNTF genotype had a marked effect on responses within the placebo group for each subscale, but not within the iloperidone group (Figures 2-4) .
BPRS
Iloperidone was also significantly more effective than placebo in improving BPRS scores in the overall patient population (p = 0.013). Within the iloperidone group, patients showed similar improvement in BPRS scores from baseline to day 28 regardless of their rs1800169 CNTF genotype (p = 0.997). However, an increased response to placebo occurred in non-G/G versus G/G patients ( Figure 5) . Consequently, iloperidone was significantly more effective than placebo in improving BPRS scores in G/G patients (p = 0.005), but not in non-G/G patients. In the overall population, iloperidone was significantly more effective than placebo in improving CGI-C (p = 0.041) and CGI-S (p = 0.007) scores from baseline to day 28. Within the iloperidone group, patients with G/G and non-G/G rs1800169 CNTF genotypes showed similar improvement in CGI-C (p = 0.934) or CGI-S (p = 0.689). There were differences in response to placebo on both scales between G/G and non-G/G patients. Iloperidone was significantly more effective than placebo in improving CGI-C (p = 0.014) and CGI-S (p = 0.004) scores in G/G patients.
Discussion
The results from this 28-day study demonstrated that iloperidone 24 mg/day was significantly more effective than placebo in improving PANSS-T, PANSS-P, PANSS-N, BPRS, CGI-C and CGI-S scores in patients with schizophrenia. Iloperidone was significantly more effective versus placebo among patients with the CNTF rs1800169 G/G genotype. Moreover, patients with the non-G/G genotype who received placebo had a greater response than the homozygous G/G patients. These observations were consistent across all efficacy measures. The differences in response between G/G and non-G/G patients who received placebo were not related to differences in baseline scores for any of the efficacy measures, which were similar across treatment groups, as well as for patients with different CNTF genotypes within each group. These observations suggest that the relative treatment benefit of iloperidone compared with placebo is enhanced among patients with schizophrenia carrying the CNTF rs1800169 G/G genotype. These results confirmed findings from the previous pharmacogenetic study. Interestingly, in the current study, patients treated with iloperidone seemed to show similar improvements from baseline regardless of their CNTF rs1800169 genotype, differing from the previous study results that suggested a greater benefit for patients with the G/G genotype. This difference between the two evaluations may be attributable, at least in part, to the larger number of patients treated with iloperidone who were genotyped in the current study (n = 279) than in the previous study (n = 90). Another potential confounding factor is the striking difference in the populations examined. In the prior study, 70% of patients were white, 24% were black and 6% were Asian or from other races; in this study, approximately 50% of patients were black, 35% were white, 9% were Asian and the remainder (6%) were from other races. In the study reported here, the effect of placebo is different between CNTF genotype groups, suggesting that the course of the disease, as well as the response to treatment may, at least in part, depend on the patient's CNTF genotype. Non-G/G patients from the placebo group showed on average a similar level of improvement compared with the G/G and non-G/G iloperidone-treated patients, but a significantly higher level than G/G patients who received placebo. Therefore, the benefit of drug therapy measured in non-G/G patients treated with iloperidone (21.9% of the iloperidone group) could be the result of either the participation in the clinical study (e.g., placebo effect, care received during the study), the pharmacological effect of iloperidone or both. The actual effective benefit of the drug may be different in patients with different CNTF genotypes even though overall, the observed improvement of symptoms is equivalent. This suggests that knowledge of the CNTF rs1800169 genotype could be taken into consideration when assessing the benefit:risk ratio of iloperidone for individual patients compared with other available therapies or alternative management of the disease.
Placebo response is a common and important factor in clinical studies of CNS indications. The placebo effect is less frequent with increasing trial duration, suggesting that such patients can relapse sooner than patients on active treatment [35] . It has been suggested that the effect of placebo may be linked to the coupling of neuronal processes with constitutive nitric oxide [36] . It has also been shown that nitric oxide can inhibit the dopamine β-hydroxylase enzyme that converts dopamine future science group future science group to norepinephrine [37] and can block the presynaptic neuronal release of dopamine [38] . Interestingly, the CNTF signaling in nerve cells has been shown to be inhibited by nitric oxide and reactive oxygen species [39] . Therefore, the findings of our study may have implications with regard to the potential genetic and physiologic mechanisms underlying placebo response, which are still in the preliminary stages of understanding. Perhaps more intriguing is the possibility that patients with different CNTF alleles represent different subtypes of schizophrenia. It has been shown that the cholinergic differentiation factors CNTF and leukemia inhibitory factor (LIF) can downregulate dopamine β-hydroxylase activity in sympathetic neurons. The FS63TER allele could therefore be expected to lead to a decrease in dopamine levels as a result of increased DBH activity. If, indeed, patients with schizophrenia who carry the G/G or non-G/G genotype have different levels of DBH activity, it is conceivable that the resulting different levels of dopamine alter their response to placebo or to various medications.
Better predictions of which patients will have, or are having, a sustainable treatment response, rather than a placebo response, will facilitate treatment selection and ongoing patient assessment, especially in this challenging disease. These results provide new insight into the effect of CNTF genotypes on the response to iloperidone, developed with the ultimate goal of directing therapy to patients with the highest benefit-to-risk ratio.
Conclusions
Iloperidone was significantly more effective than placebo across all measures in patients who were homozygote G/G for the CNTF rs1800169 polymorphism. This is the first clinical trial report showing an effect of CNTF 
Executive summary
Aims
• This trial aimed to prospectively evaluate CNTF rs1800169 genotype effects on response to iloperidone.
Patients & methods
• This 28-day, double-blind study randomized in-patients with schizophrenia to receive iloperidone 24 mg/day, an active comparator or placebo. • Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) measured efficacy response; pharmacogenetic efficacy analysis was a prospective step-down primary end point.
• Treatment efficacy was compared between rs1800169 G/G and non-G/G genotypes.
Results
• Efficacy was evaluated for 417 genotyped patients (279 iloperidone and 138 placebo).
• Iloperidone significantly improved PANSS total (PANSS-T), PANSS positive subscale (PANSS-P), PANSS negative subscale (PANSS-N), BPRS, CGI of Change (CGI-C) and CGI of Severity (CGI-S) scores versus placebo; G/G and non-G/G patients responded similarly to iloperidone. • rs1800169 CNTF genotype appeared to influence placebo response, as non-G/G patients receiving placebo responded better than G/G patients on all measures. • G/G versus non-G/G patients had greater improvement with iloperidone versus placebo in PANSS-T, PANSS-P, PANSS-N, PANSS-GP, BPRS, CGI-C and CGI-S.
Conclusions
• Iloperidone was significantly more effective than placebo in rs1800169 G/G patients across all measures, but patients with the non-G/G genotype responded similarly to iloperidone and placebo.
• This is the first clinical trial report showing an effect of CNTF polymorphism on schizophrenia treatment response. Such markers may allow individualized treatment of schizophrenia by identifying likely responders.
Future perspective
• Treatment response, safety outcomes and tolerability for medications may be better understood based on pharmacogenetic research, and this can lead to individualized treatment for patients.
